MX2021006036A - Formulacion inyectable de liberacion sostenida de naltrexona. - Google Patents

Formulacion inyectable de liberacion sostenida de naltrexona.

Info

Publication number
MX2021006036A
MX2021006036A MX2021006036A MX2021006036A MX2021006036A MX 2021006036 A MX2021006036 A MX 2021006036A MX 2021006036 A MX2021006036 A MX 2021006036A MX 2021006036 A MX2021006036 A MX 2021006036A MX 2021006036 A MX2021006036 A MX 2021006036A
Authority
MX
Mexico
Prior art keywords
sustained release
naltrexone
pharmaceutical formulation
injectable sustained
release formulation
Prior art date
Application number
MX2021006036A
Other languages
English (en)
Inventor
Tong-Ho Lin
Yung-Shun Wen
Ying-Ting Liu
zhi-rong Wu
Original Assignee
Alar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc filed Critical Alar Pharmaceuticals Inc
Publication of MX2021006036A publication Critical patent/MX2021006036A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona una formulación farmacéutica inyectable de liberación sostenida, que incluye 3-acil-naltrexona o una sal farmacéuticamente aceptable de la misma, un disolvente orgánico biocompatible y, de forma opcional, un material polimérico biocompatible. También se proporciona un método para tratar el trastorno por consumo de opioides o el alcoholismo, que incluye la administración de la formulación farmacéutica inyectable de liberación sostenida a un sujeto que la necesita. La formulación farmacéutica proporciona un perfil de liberación sostenida después de una sola inyección, y los niveles plasmáticos de naltrexona en minicerdos podrían proporcionar una liberación sostenida durante 2 meses.
MX2021006036A 2018-12-27 2019-12-26 Formulacion inyectable de liberacion sostenida de naltrexona. MX2021006036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785259P 2018-12-27 2018-12-27
PCT/CN2019/128663 WO2020135576A1 (en) 2018-12-27 2019-12-26 Naltrexone injectable sustained release formulation

Publications (1)

Publication Number Publication Date
MX2021006036A true MX2021006036A (es) 2021-07-06

Family

ID=71125739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006036A MX2021006036A (es) 2018-12-27 2019-12-26 Formulacion inyectable de liberacion sostenida de naltrexona.

Country Status (11)

Country Link
US (1) US20220062277A1 (es)
EP (1) EP3902526A4 (es)
JP (1) JP2022516720A (es)
KR (1) KR20210110825A (es)
CN (1) CN113226288B (es)
AU (1) AU2019416507A1 (es)
BR (1) BR112021012210A2 (es)
CA (1) CA3118921A1 (es)
MX (1) MX2021006036A (es)
TW (1) TWI827777B (es)
WO (1) WO2020135576A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023090922A1 (ko) * 2021-11-18 2023-05-25 (주)인벤티지랩 날트렉손을 포함하는 서방성 주사용 조성물 및 이의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US7919499B2 (en) * 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
EP3141241A1 (en) * 2015-09-08 2017-03-15 Andreas Voigt Sustained release low dose formulations and uses thereof
WO2017100863A1 (en) * 2015-12-17 2017-06-22 Verita Research Pte Ltd Injectable composition and a method of treatment of the physical addiction
TWI743193B (zh) * 2016-09-13 2021-10-21 昱展新藥生技股份有限公司 丁基原啡因緩釋製劑
EP3703694A4 (en) * 2017-11-03 2021-08-18 Nirsum Laboratories, Inc. MEDICINES ANTAGONISTS OF OPIOID RECEPTORS

Also Published As

Publication number Publication date
EP3902526A4 (en) 2022-11-30
AU2019416507A1 (en) 2021-06-03
CN113226288B (zh) 2023-04-28
JP2022516720A (ja) 2022-03-02
BR112021012210A2 (pt) 2021-08-31
EP3902526A1 (en) 2021-11-03
WO2020135576A1 (en) 2020-07-02
CN113226288A (zh) 2021-08-06
KR20210110825A (ko) 2021-09-09
US20220062277A1 (en) 2022-03-03
TW202038910A (zh) 2020-11-01
TWI827777B (zh) 2024-01-01
CA3118921A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
Kim et al. Antinociceptive mechanisms associated with diluted bee venom acupuncture (apipuncture) in the rat formalin test: involvement of descending adrenergic and serotonergic pathways
MX2021008247A (es) Combinacion de dextrometorfano y bupropion para el tratamiento de depresion.
PH12018550210A1 (en) Oral dosage form with drug composition, barrier layer and drug layer
EA201401348A1 (ru) Технология приготовления имплантируемой формы палиперидона
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
NZ627368A (en) Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MX2018013973A (es) Metodos de tratamiento de sindromes de comportamiento usando pipradrol.
AU2017312811A8 (en) Liquid naloxone spray
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
EA201790721A1 (ru) Инъекционный состав бупренорфина
MX2019003373A (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2021006036A (es) Formulacion inyectable de liberacion sostenida de naltrexona.
EA202192878A1 (ru) Способ лечения ребенка с преждевременным половым созреванием центрального генеза с использованием композиции с пролонгированным высвобождением
PH12020500032A1 (en) Isotretinoin oral-mucosal fromulations and methods for using same
RU2016137289A (ru) Схема применения соединения fgf-18
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP4265298A3 (en) Salt
CO2020000529A2 (es) Metodos para tratar hiperinsulinismo congenito
NZ760033A (en) Methods to treat opioid use disorder
MX2020005438A (es) Formas de dosificacion de sulfato de morfina disuasivas del abuso.
Javidan et al. A novel controlled release drug delivery system for naltrexone administration combined with intermittent morphine to induce antinociception